Target Price | $155.04 |
Price | $132.22 |
Potential | 17.26% |
Number of Estimates | 32 |
32 Analysts have issued a price target Biogen 2026 . The average Biogen target price is $155.04. This is 17.26% higher than the current stock price. The highest price target is $273.00 106.47% , the lowest is $119.18 9.86% . | |
A rating was issued by 43 analysts: 20 Analysts recommend Biogen to buy, 22 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2026 of 17.26% . Most analysts recommend the Biogen stock at Hold. |
37 Analysts have issued a sales forecast Biogen 2025 . The average Biogen sales estimate is $9.9b . This is 1.28% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $10.5b 5.34% , the lowest is $9.3b 6.73% .
This results in the following potential growth metrics:
2024 | $9.7b | 1.62% |
---|---|---|
2025 | $9.9b | 2.00% |
2026 | $9.5b | 4.03% |
2027 | $9.5b | 0.24% |
2028 | $9.7b | 1.75% |
2029 | $9.7b | 0.05% |
2030 | $9.6b | 1.02% |
2031 | $9.4b | 1.62% |
2032 | $9.4b | 0.37% |
17 Analysts have issued an Biogen EBITDA forecast 2025. The average Biogen EBITDA estimate is $3.4b . This is 5.28% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.0b 23.88% , the lowest is $3.0b 7.18% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $3.0b | 25.80% |
---|---|---|
2025 | $3.4b | 10.70% |
2026 | $3.5b | 3.18% |
2027 | $3.5b | 0.84% |
2028 | $3.9b | 11.69% |
2029 | $4.0b | 2.25% |
2030 | $4.0b | 0.80% |
2031 | $5.6b | 40.79% |
2032 | $6.1b | 9.78% |
2024 | 31.40% | 27.87% |
---|---|---|
2025 | 34.08% | 8.55% |
2026 | 36.64% | 7.51% |
2027 | 36.85% | 0.57% |
2028 | 40.46% | 9.80% |
2029 | 41.39% | 2.30% |
2030 | 41.48% | 0.22% |
2031 | 59.36% | 43.11% |
2032 | 64.93% | 9.38% |
38 Biogen Analysts have issued a net profit forecast 2025. The average Biogen net profit estimate is $2.4b . This is 55.07% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.5b 62.75% , the lowest is $2.2b 45.59% .
This results in the following potential growth metrics and future Net Margins:
2024 | $1.6b | 40.57% |
---|---|---|
2025 | $2.4b | 45.41% |
2026 | $2.4b | 0.44% |
2027 | $2.5b | 3.98% |
2028 | $2.6b | 4.13% |
2029 | $2.6b | 0.36% |
2030 | $2.5b | 4.06% |
2031 | $2.5b | 0.56% |
2032 | $2.5b | 2.88% |
2024 | 16.87% | 42.89% |
---|---|---|
2025 | 24.05% | 42.57% |
2026 | 24.95% | 3.74% |
2027 | 25.88% | 3.73% |
2028 | 26.48% | 2.32% |
2029 | 26.59% | 0.42% |
2030 | 25.77% | 3.08% |
2031 | 26.35% | 2.25% |
2032 | 27.01% | 2.50% |
38 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is $16.19 . This is 55.23% higher than earnings per share in the financial year 2024. The highest EPS forecast is $16.99 62.90% , the lowest is $15.20 45.73% .
This results in the following potential growth metrics and future valuations:
2024 | $11.19 | 40.40% |
---|---|---|
2025 | $16.19 | 44.68% |
2026 | $16.12 | 0.43% |
2027 | $16.76 | 3.97% |
2028 | $17.45 | 4.12% |
2029 | $17.51 | 0.34% |
2030 | $16.80 | 4.05% |
2031 | $16.90 | 0.60% |
2032 | $17.38 | 2.84% |
Current | 12.68 | 50.90% |
---|---|---|
2025 | 8.17 | 35.55% |
2026 | 8.20 | 0.37% |
2027 | 7.89 | 3.78% |
2028 | 7.58 | 3.93% |
2029 | 7.55 | 0.40% |
2030 | 7.87 | 4.24% |
2031 | 7.83 | 0.51% |
2032 | 7.61 | 2.81% |
Based on analysts' sales estimates for 2025, the Biogen stock is valued at an EV/Sales of 2.32 and an P/S ratio of 1.96 .
This results in the following potential growth metrics and future valuations:
Current | 2.29 | 35.31% |
---|---|---|
2025 | 2.32 | 1.37% |
2026 | 2.42 | 4.20% |
2027 | 2.41 | 0.24% |
2028 | 2.37 | 1.72% |
2029 | 2.37 | 0.05% |
2030 | 2.40 | 1.02% |
2031 | 2.44 | 1.65% |
2032 | 2.43 | 0.37% |
Current | 1.94 | 37.19% |
---|---|---|
2025 | 1.96 | 1.30% |
2026 | 2.05 | 4.20% |
2027 | 2.04 | 0.24% |
2028 | 2.01 | 1.72% |
2029 | 2.01 | 0.05% |
2030 | 2.03 | 1.03% |
2031 | 2.06 | 1.65% |
2032 | 2.05 | 0.37% |
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Aug 14 2025 |
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Aug 01 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Aug 01 2025 |
Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 01 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jun 27 2025 |
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Aug 14 2025 |
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Aug 01 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Aug 01 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Aug 01 2025 |
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 01 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jun 27 2025 |
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Jun 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.